Analysts think NCNA stock price could increase by 4198%
Aug 02, 2024, 6:25 AM
-1.97%
What does NCNA do
NuCana Plc, a clinical stage biopharmaceutical company, leverages its ProTide technology to enhance cancer treatment, with key drugs like NUC-3373 and NUC-7738 currently in clinical trials. NUC-3373 targets advanced colorectal cancer, while NUC-7738, a transformation of 3’-deoxyadenosine, is being tested in patients with advanced solid tumors.
4 analysts think NCNA stock price will increase by 4197.75%. The current median analyst target is $153.00 compared to a current stock price of $3.56. The lowest analysts target is $151.50 and the highest analyst target is $157.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.